Ventrus Biosciences IMPLODES 58% and 4 Stocks with Horrible News Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

The FDA has sought an update, not a new trial, regarding data management and verification from a study of the treatment of Eliquis the new drug from Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) which helps prevent strokes inpatients suffering from non-valvular atrial fibrillation.

Don’t Miss: Is Chesapeake GUILTY of This DAMNING Charge?

In the never-ending run of scandals at Chesapeake (NYSE:CHK), Reuters has exposed a fresh one, this time involving the suppression of land prices allegedly in collusion with Encana (NYSE:ECA) in many deals in Michigan. Apparently Reuters has reviewed emails that go to show Aubrey McClendon directed the operation and may be evidence of violation of federal and state price-fixing laws .

Shares of Ventrus Biosciences (NASDAQ:VTUS) tanked more than 50 percent after its iferanserin drug for hemorrhoidal disease failed phase 3 trials for the elimination of bleeding, itching and pain. Reportedly, Ventrus has aborted further development of the the drug and will move on to its other compounds.

Don’t Miss: Here’s the ONLY WAY to SAVE the U.S. Middle Class.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business